Sandbox: treatment

Revision as of 21:03, 22 September 2015 by Haytham Allaham (talk | contribs)
Jump to navigation Jump to search

Multiple myeloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple Myeloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Sandbox: treatment On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox: treatment

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox: treatment

CDC on Sandbox: treatment

Sandbox: treatment in the news

Blogs on Sandbox: treatment

Directions to Hospitals Treating Multiple myeloma

Risk calculators and risk factors for Sandbox: treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Patients with smoldering (asymptomatic) multiple myeloma are managed by observation and undergoing follow up tests every 3 to 6 months. Whereas patients with active (symptomatic) multiple myeloma are treated with a combination of steroid therapy, immune modulator therapy and chemotherapy. The optimal therapy for active multiple myeloma depends on whether or not a patient is eligible for bone marrow transplantation. Patients who are candidates for bone marrow transplantation are treated by a combination of dexamethasone and lenalidomide/bortezomib in advance to their transplantation. Alkylating agents are not recommended among transplant eligible patients, as the toxicity of such agents makes the harvest of bone marrow stem cell difficult later in the course. Other pharmacological regimes used to treat active multiple myeloma patients eligible for bone marrow transplant may include either thalidomide, carfilzomib, cyclophosphamide, vincristine, or doxorubicin. In addition to the aforementioned agents, pharmacological regimes used for treatment of active multiple myeloma patients who are not eligible for bone marrow transplantation may include either melphalan or prednisone.

Medical Therapy

Smoldering multiple myeloma

  • Patients with smoldering (asymptomatic) multiple myeloma are managed by observation and follow up tests every 3 to 6 months.
  • Follow up studies of asymptomatic multiple myeloma patients include:
    • Laboratory studies such as complete blood count, blood chemistry, 24 hour urine collection, electrophoresis, and quantitative immunoglobulin analysis
    • Imaging studies such as skeletal survey, MRI, and PET scan
    • Flow cytometry as needed
    • Bone marrow aspiration and biopsy as needed
  • Treatment should be differed until such patients develop symptoms.

Active multiple myeoloma

  • The optimal therapy for active multiple myeloma depends on whether or not a patient is eligible for bone marrow transplantation.
  • Deciding whether a patient is a candidate for bone marrow transplantation depends on a number of key factors that include:
    • Age
    • Presence of current associated diseases
    • Patient's liver function
    • Patient's kidney function
    • Patient's cardiac function

Bone marrow transplant eligible patients

  • Preferred pharmacological regimes for treating such patients include:
  • Bortezomib/dexamethasone
  • Bortezomib/dexamethasone/lenalidomide
  • Dexamethasone/lenalidomide
  • Bortezomib/dexamethasone/doxorubicin
  • Bortezomib/dexamethasone/thalidomide
  • Bortezomib/dexamethasone/cyclophosphamide

Bone marrow transplant ineligible patients

  • Preferred pharmacological regimes for treating such patients include:
  • Bortezomib/dexamethasone
  • Low dose dexamethasone/lenalidomide
  • Melphalan/prednisone/thalidomide
  • Melphalan/prednisone/bortezomib

Supportive therapy

  • Supportive therapy is recommended based on patient's symptoms and medication's side effects.
  • Supportive therapy for active multiple myeloma includes:
  • Bisphosphonates to prevent osteoporosis
  • Erythropoietin to prevent anemia
  • Vaccines to prevent recurrent infections
  • Blood thinners to prevent blood clots
  • Plasmapheresis to prevent hyperviscosity and renal failure



References


Template:WikiDoc Sources